We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government.
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together if there is no alternative and closely monitor patients for signs of respiratory depression.
Crime and Policing Minister Kit Malthouse has today announced that 3 benzodiazepines will be made Class C drugs.
A review of the evidence of use and harms of novel benzodiazepines.
Supporting safer use
Advice for medical professionals to follow when assessing drivers with drug or alcohol misuse or dependence.
A change to the Misuse of Drugs Act 1971 to control 3 benzodiazepines (flualprazolam, flunitrazolam and norfludiazepam) under Class C.
Atnahs Pharma UK Ltd has informed the MHRA that the batches of Clobazam Atnahs 5mg/5ml and 10mg/5ml Oral Suspension listed in this notification do not contain the most up to date safety information.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.